Lets debunk the myths about this natural bodily compound, which has been garnering attention lately
Additionally, new data presented at the ADA conference shed light on the potential benefits of combined therapy with SGLT2 inhibitors
Though the AAOph and the North American Neuro-Ophthalmology Society do not recommend that people stop taking semaglutide at this time, they reiterate that further research will help clarify the relationship between the drug and ocular events such as NAION.
00:00:12 Narrator On this episode, associate editor and clinical pharmacist, Vicki Danaher, shares practical guidance on how Orforglopron, the second oral GLP-1 agonist for weight loss, stacks up against oral semaglutide in terms of dosing, efficacy, safety, cost, and more in an excerpt from our popular Pharmacy Essential Updates webinar series
No clinical evidence suggests any negative interaction between the two
J., & Amrein, R